Overview

A Phase II Clinical Study to Evaluate HLX43 in Patients With Locally Advanced or Metastatic HCC Failed or Intolerance to Standard Therapy

Status:
RECRUITING
Trial end date:
2027-06-05
Target enrollment:
Participant gender:
Summary
The study is being conducted to to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma (HCC) Failed or Intolerance to Standard Therapy
Phase:
PHASE2
Details
Lead Sponsor:
Shanghai Henlius Biotech